• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Adolescent Health, Medicine and Therapeutics >Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions
【24h】

Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions

机译：阿达木单抗在儿童和青少年特发性关节炎和其他风湿病的治疗中的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Treatment of children and adolescents with juvenile idiopathic arthritis and other pediatric rheumatic diseases has evolved. Where once there was only a limited arsenal of medications, with significant side effects and inadequate efficacy, today, with an increased understanding of the pathogenesis of these diseases, there is a wider variety of more targeted and effective treatments. TNF-α is a cytokine involved in a number of inflammatory pathways in pediatric rheumatic diseases. The emergence of biologic modifiers that target TNF-α has been pivotal in providing the ability to deliver early and aggressive treatment. Adalimumab, a recombinant monoclonal antibody to TNF-α, is an important therapeutic option, which affords children and adolescents with chronic illnesses an improved quality of life.
机译：发展了对儿童特发性关节炎和其他小儿风湿性疾病的儿童和青少年的治疗。在曾经只有有限的药物库，具有显着的副作用和功效不足的地方，如今，随着对这些疾病的发病机理的了解日益加深，出现了更多种类的更有针对性和有效的治疗方法。 TNF-α是一种参与小儿风湿病多种炎症途径的细胞因子。靶向TNF-α的生物修饰剂的出现对于提供早期和积极治疗的能力至关重要。阿达木单抗是一种针对TNF-α的重组单克隆抗体，是一种重要的治疗选择，它可以为患有慢性疾病的儿童和青少年提供更高的生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号